Tag: QuiremSpheres

Dose-response relation confirmed for Holmium-166 (QuiremSpheres®) SIRT

Quirem Medical is pleased to share that yet another Holmium-166 (QuiremSpheres®) related scientific article has been published, after recently having reported on the publication of Smits et al. on the superior predictive value of 166Ho-Scout (QuiremScout®) compared to 99mTc-MAA as a SIRT work-up. This new, corner-stone publication by Bastiaannet et

Read More »

Radboudumc performs their first QuiremSpheres® treatment

We are pleased to announce that the Radboudumc in Nijmegen has treated its first patient with QuiremSpheres®. This milestone has been made possible by an interdisciplinary team, consisting of Dr. Marcel Janssen (Nuclear Medicine physician), Dr. Mark Arntz (Interventional Radiologist), as well  other hospital staff and technicians. The patient suffering

Read More »

QuiremSpheres® Observational Study

On June 7th the first site of the QuiremSpheres® Observational Study, the Universitätsklinikum Carl Gustav Carus in Dresden, Germany, was opened for registration. The observational study aims to further confirm treatment safety and efficacy using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases.

Read More »

First patient at the Istituto Nazionale dei Tumori hospital in Milan, Italy

On May 22th 2018, the first patient at the Istituto Nazionale dei Tumori was treated with QuiremSpheres®. The team, led by Prof. Dr. Mazzaferro (surgeon), Dr. Bhoori (hepatologist), Dr. Maccauro (nuclear medicine), Dr. Carlo Spreafico (Interventional Radiology) and Dr. Chieza (medical physics) used QuiremSpheres® for treatment of a patient suffering from

Read More »